Office-based Solution Zenflow's Spring System enables in-office, atraumatic treatment for urinary obstruction due to BPH, offering a less invasive alternative to surgery with positive four-year trial insights. This positions urology practices and ambulatory surgery centers as primary buyers seeking efficient, outpatient workflows and reduced procedure risk.

Large TAM There is a large addressable market for BPH-related obstruction—tens of millions of US men and hundreds of millions worldwide—where drugs often fail and many patients avoid invasive procedures. Zenflow’s in-office device addresses this gap, creating sales opportunities with high-volume clinics and health systems expanding outpatient options.

Clinical Credibility Clinical validation underpins credibility: the BREEZE pivotal trial has shown favorable outcomes up to four years post-treatment. Investor backing, including Cook Medical in the Series C round of about $24 million, signals readiness to scale manufacturing, field teams, and distribution partnerships.

Strategic Partnerships Cook Medical’s participation in the Series C highlights potential for distribution, co-development, or OEM partnerships. Zenflow can leverage these relationships to accelerate market entry through established urology channels and medical device distributors.

Growth Readiness With 11-50 employees and revenue in the lower to mid single-digit millions, Zenflow is positioned to scale its field-based sales and clinical education efforts. Active participation in industry events such as the American Urological Association annual meeting demonstrates momentum and demand creation.